Next Article in Journal
Activity of 2-benzyl-1-(2-hydroxyethyl)-5-nitroindazolin-3-one on Trypanosoma cruzi Bloodstream Trypomastigotes (Y strain): In Vitro and In Vivo Studies
Previous Article in Journal
Antibiotic Translocation and Membrane Barrier: New Insights to Combat Bacterial Resistance Jean-Marie Pagès UMR_MD1, TMCD2, Aix-Marseille Univ, IRBA, Marseille, France
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Highly Sensitive Bioluminescence Imaging Models for Chagas Disease Drug Discovery †

London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
*
Author to whom correspondence should be addressed.
Presented at the 1st Molecules Medicinal Chemistry Symposium, Barcelona, Spain, 8 September 2017.
Proceedings 2017, 1(6), 676; https://doi.org/10.3390/proceedings1060676
Published: 17 October 2017
Chagas disease is caused by the insect-transmitted protozoan Trypanosoma cruzi, and is the most important parasitic infection in Latin America. As a result of migration, it is also emerging as a public health issue in non-endemic regions, particularly in the US and Europe. Infections with T. cruzi are life-long, and lead to cardiomyopathy in 20–30% of cases. A causal link between cardiac infection and pathology has been difficult to establish because of a lack of robust methods to detect scarce focally distributed parasites within tissues. By combining highly sensitive bioluminescence imaging and fluorescence technology, we have developed procedures which have allowed us to track infection dynamics, quantify tissue-specific parasite loads, and provide new insights into parasite biology in predictive murine models. These approaches have identified the gut as the major reservoir site during chronic infections. In this presentation, we review the parameters of the imaging systems and describe how these experimental models can be incorporated into drug-development programmes as a valuable tool for assessing efficacy against both acute and chronic T. cruzi infections.

Author Contributions

All authors contributed to design of the study. Experiments were performed by A.F.F., S.J., M.C.T. and M.D.L. and J.M.K. wrote the abstract. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

We acknowledge funding from the British Heart Foundation and the Drugs for Neglected Diseases Initiative (DNDi).

Conflicts of Interest

The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Kelly, J.M.; Francisco, A.F.; Jayawardhana, S.; Taylor, M.C.; Lewis, M.D. Highly Sensitive Bioluminescence Imaging Models for Chagas Disease Drug Discovery. Proceedings 2017, 1, 676. https://doi.org/10.3390/proceedings1060676

AMA Style

Kelly JM, Francisco AF, Jayawardhana S, Taylor MC, Lewis MD. Highly Sensitive Bioluminescence Imaging Models for Chagas Disease Drug Discovery. Proceedings. 2017; 1(6):676. https://doi.org/10.3390/proceedings1060676

Chicago/Turabian Style

Kelly, John M., Amanda F. Francisco, Shiromani Jayawardhana, Martin C. Taylor, and Michael D. Lewis. 2017. "Highly Sensitive Bioluminescence Imaging Models for Chagas Disease Drug Discovery" Proceedings 1, no. 6: 676. https://doi.org/10.3390/proceedings1060676

APA Style

Kelly, J. M., Francisco, A. F., Jayawardhana, S., Taylor, M. C., & Lewis, M. D. (2017). Highly Sensitive Bioluminescence Imaging Models for Chagas Disease Drug Discovery. Proceedings, 1(6), 676. https://doi.org/10.3390/proceedings1060676

Article Metrics

Back to TopTop